Unknown

Dataset Information

0

Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon.


ABSTRACT: Oxaliplatin is a platinum-based chemotherapeutic used for cancer treatment. Its use associates with peripheral neuropathies and chronic gastrointestinal side-effects. Oxaliplatin induces immunogenic cell death by provoking the presentation of damage associated molecular patterns. The damage associated molecular patterns high-mobility group box 1 (HMGB1) protein exerts pro-inflammatory cytokine-like activity and binds to toll-like receptors (namely TLR4). Gastrointestinal microbiota may influence chemotherapeutic efficacy and contribute to local and systemic inflammation. We studied effects of oxaliplatin treatment on 1) TLR4 and high-mobility group box 1 expression within the colon; 2) gastrointestinal microbiota composition; 3) inflammation within the colon; 4) changes in Peyer's patches and mesenteric lymph nodes immune populations in mice. TLR4+ cells displayed pseudopodia-like extensions characteristic of antigen sampling co-localised with high-mobility group box 1 -overexpressing cells in the colonic lamina propria from oxaliplatin-treated animals. Oxaliplatin treatment caused significant reduction in Parabacteroides and Prevotella1, but increase in Prevotella2 and Odoribacter bacteria at the genus level. Downregulation of pro-inflammatory cytokines and chemokines in colon samples, a reduction in macrophages and dendritic cells in mesenteric lymph nodes were found after oxaliplatin treatment. In conclusion, oxaliplatin treatment caused morphological changes in TLR4+ cells, increase in gram-negative microbiota and enhanced HMGB1 expression associated with immunosuppression in the colon.

SUBMITTER: Stojanovska V 

PROVIDER: S-EPMC5997344 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon.

Stojanovska Vanesa V   McQuade Rachel M RM   Fraser Sarah S   Prakash Monica M   Gondalia Shakuntla S   Stavely Rhian R   Palombo Enzo E   Apostolopoulos Vasso V   Sakkal Samy S   Nurgali Kulmira K  

PloS one 20180612 6


Oxaliplatin is a platinum-based chemotherapeutic used for cancer treatment. Its use associates with peripheral neuropathies and chronic gastrointestinal side-effects. Oxaliplatin induces immunogenic cell death by provoking the presentation of damage associated molecular patterns. The damage associated molecular patterns high-mobility group box 1 (HMGB1) protein exerts pro-inflammatory cytokine-like activity and binds to toll-like receptors (namely TLR4). Gastrointestinal microbiota may influence  ...[more]

Similar Datasets

| S-EPMC2962643 | biostudies-literature
| S-EPMC4491963 | biostudies-literature
| S-EPMC3697986 | biostudies-literature
| S-EPMC7069102 | biostudies-literature
| S-EPMC10584754 | biostudies-literature
| S-EPMC3242515 | biostudies-other
| S-EPMC4470690 | biostudies-literature
| S-EPMC7053597 | biostudies-literature
| S-EPMC8631436 | biostudies-literature
| S-EPMC10136752 | biostudies-literature